Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study.
Hara S, Mori K, Fukuokaya W, Tomomasa N, Oguchi T, Takahashi Y, Saito S, Katami J, Sano T, Kadena S, Hashimoto M, Yata Y, Nishi E, Suhara Y, Takamizawa S, Kurawaki S, Suzuki H, Miyajima K, Iwatani K, Urabe F, Ito K, Yanagisawa T, Tsuzuki S, Shimomura T, Kimura T. Hara S, et al. Among authors: fukuokaya w. Int J Clin Oncol. 2024 May 20. doi: 10.1007/s10147-024-02548-6. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38769191
Perioperative renal function change and oncological outcomes of radical nephroureterectomy in patients with upper tract urothelial carcinoma: A multicenter retrospective study.
Muramoto K, Urabe F, Koike Y, Yamamoto S, Suzuki H, Miyajima K, Fukuokaya W, Iwatani K, Imai Y, Igarashi T, Mori K, Aikawa K, Kimura S, Tashiro K, Yamada Y, Sasaki T, Sato S, Yuen SKK, Shimomura T, Furuta A, Tsuzuki S, Miki J, Kimura T; JIKEI-YAYOI Collaborative Group. Muramoto K, et al. Among authors: fukuokaya w. Urol Oncol. 2024 May 9:S1078-1439(24)00421-6. doi: 10.1016/j.urolonc.2024.04.001. Online ahead of print. Urol Oncol. 2024. PMID: 38729868
Radiographic Progression Without Corresponding Prostate-specific Antigen Progression in Patients with Metastatic Castration-sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial.
Fukuokaya W, Yanagisawa T, Mori K, Urabe F, Rajwa P, Briganti A, Shariat SF, Kimura T. Fukuokaya W, et al. Eur Urol Oncol. 2024 Apr 29:S2588-9311(24)00101-9. doi: 10.1016/j.euo.2024.04.009. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38688767
Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate Cancer.
Tashiro K, Kimura S, Tsuzuki S, Urabe F, Fukuokaya W, Mori K, Aikawa K, Murakami M, Sasaki H, Miki K, Miki J, Shimomura T, Yamada H, Hata K, Nishikawa H, Abe H, Watanabe K, Kimura T. Tashiro K, et al. Among authors: fukuokaya w. Clin Genitourin Cancer. 2024 Mar 21;22(3):102075. doi: 10.1016/j.clgc.2024.102075. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 38643665
Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a Multicenter Cohort Study.
Narita C, Urabe F, Fukuokaya W, Iwatani K, Imai Y, Yasue K, Mori K, Aikawa K, Yanagisawa T, Kimura S, Tashiro K, Tsuzuki S, Yamada Y, Yuen SKK, Teoh JY, Shimomura T, Yamada H, Furuta A, Miki J, Kimura T; JIKEI-YAYOI Collaborative Group. Narita C, et al. Among authors: fukuokaya w. Clin Genitourin Cancer. 2024 Mar 21:102082. doi: 10.1016/j.clgc.2024.102082. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 38641443
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y, Adachi T, Hashimoto T, Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, Nishimura K, Takahara K, Saruta M, Fujita K, Hashimoto M, Uemura H, Shiroki R, Azuma T, Kimura T, Ohno Y. Hirasawa Y, et al. Among authors: fukuokaya w. J Cancer Res Clin Oncol. 2024 Apr 9;150(4):182. doi: 10.1007/s00432-024-05717-2. J Cancer Res Clin Oncol. 2024. PMID: 38592548 Free PMC article.
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T, Tsuchida S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Higashio T, Matsuda T, Nishimura K, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Fujita K, Kimura T, Ohno Y, Shiroki R, Uemura H, Azuma H. Uchimoto T, et al. Among authors: fukuokaya w. Target Oncol. 2024 May;19(3):401-410. doi: 10.1007/s11523-024-01047-y. Epub 2024 Mar 28. Target Oncol. 2024. PMID: 38546942
Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.
Hashimoto M, Fukuokaya W, Yanagisawa T, Yamamoto S, Koike Y, Imai Y, Iwatani K, Onuma H, Ito K, Urabe F, Tsuzuki S, Kimura S, Oyama Y, Abe H, Miki J, Kimura T. Hashimoto M, et al. Among authors: fukuokaya w. Int J Clin Oncol. 2024 May;29(5):612-619. doi: 10.1007/s10147-024-02482-7. Epub 2024 Mar 2. Int J Clin Oncol. 2024. PMID: 38430304
64 results